Scholar Rock slips as investors refocus on apitegromab resubmission timing and funding
Scholar Rock (SRRK) slid 3.16% to $42.63 as traders digested its latest FDA-timing and funding backdrop rather than a fresh catalyst. The company recently said apitegromab’s BLA resubmission depends on a successful FDA reinspection of Catalent Indiana and highlighted a new debt facility of up to $550 million.
1. What’s moving the stock
Scholar Rock shares were lower in Friday trading, extending a period of catalyst-driven volatility where day-to-day moves are often tied to sentiment around the apitegromab regulatory path rather than new trial data. With no new company headline clearly explaining the dip, today’s decline looks consistent with routine profit-taking and positioning ahead of the next regulatory milestone: the FDA reinspection needed before the company can resubmit its apitegromab Biologics License Application (BLA).
2. The key overhang: FDA reinspection before BLA resubmission
In its March 3, 2026 update, Scholar Rock reiterated that apitegromab BLA resubmission and a U.S. launch are anticipated in 2026, but explicitly tied the resubmission to a successful FDA reinspection of Catalent Indiana, a third-party facility involved in fill-finish operations. The company also said a recent FDA meeting with Catalent Indiana was constructive and that no additional corrective actions were requested, but the stock remains sensitive to the timing and outcome of the reinspection and subsequent resubmission steps.
3. Funding and dilution sensitivity remains in focus
Scholar Rock also highlighted a new non-dilutive debt facility providing up to $550 million to support commercialization and pipeline execution, alongside a reported cash balance of $367.6 million as of December 31, 2025. Even with added financing flexibility, biotech trading can remain skittish around future capital needs, including the potential for equity issuance, particularly when a company’s near-term valuation hinges on regulatory execution.